Selective L-nitroargininylaminopyrrolidine and L-nitroargininylaminopiperidine Neuronal Nitric Oxide Synthase Inhibitors
Overview
Chemistry
Affiliations
Selective inhibition of the localized excess production of NO by neuronal nitric oxide synthase (nNOS) has been targeted as a potential means of treating various neurological disorders. Based on observations from the X-ray crystal structures of complexes of nNOS with two nNOS-selective inhibitors, (4S)-N-{4-amino-5-[(2-amino)ethylamino]pentyl}-N'-nitroguanidine (L-Arg(NO2)-L-Dbu-NH2 (1) and 4-N-(Nomega-nitro-L-argininyl)-trans-4-amino-L-proline amide (2), a series of descarboxamide analogues was designed and synthesized (3-7). The most potent compound was aminopyrrolidine analogue 3, which exhibited better potency and selectivity for nNOS than parent compound 2. In addition, 3 provided higher lipophilicity and a lower molecular weight than 2, therefore having better physicochemical properties. Nalpha-Methylated analogues (8-11) also were prepared for increased lipophilicity of the inhibitors, but they had 4- to 5-fold weaker binding affinity compared to their parent compounds.
Clickable Polyprolines from Azido-proline -Carboxyanhydride.
Detwiler R, McPartlon T, Coffey C, Kramer J ACS Polym Au. 2023; 3(5):383-393.
PMID: 37841952 PMC: 10571246. DOI: 10.1021/acspolymersau.3c00011.
Mauchauffee E, Leroy J, Chamcham J, Ejjoummany A, Maurel M, Nauton L Molecules. 2023; 28(13).
PMID: 37446746 PMC: 10343299. DOI: 10.3390/molecules28135085.
Automated Radiosynthesis of - and -4-[F]Fluoro-l-proline Using [F]Fluoride.
Morgan T, Riley L, Tavares A, Sutherland A J Org Chem. 2021; 86(20):14054-14060.
PMID: 33913318 PMC: 8524414. DOI: 10.1021/acs.joc.1c00755.
Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain.
Mukherjee P, Cinelli M, Kang S, Silverman R Chem Soc Rev. 2014; 43(19):6814-38.
PMID: 24549364 PMC: 4138306. DOI: 10.1039/c3cs60467e.
Arginine-based inhibitors of nitric oxide synthase: therapeutic potential and challenges.
Vitecek J, Lojek A, Valacchi G, Kubala L Mediators Inflamm. 2012; 2012:318087.
PMID: 22988346 PMC: 3441039. DOI: 10.1155/2012/318087.